BURLINGTON, Mass. & NEW YORK / Feb 22, 2024 / Business Wire / Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a digital health company transforming care with handheld, whole-body ultrasound, today announced that it will host an Investor Day on Monday March 18, 2024, beginning at 12:00pm ET at the New York Stock Exchange.
During the event, Butterfly’s executive management team will present the Company’s product, software and services portfolio within the point-of-care ultrasound landscape, as well as its strategic initiatives, technology roadmap, and overarching vision. The agenda will include live demonstrations of products, including the newly released, next-generation Butterfly iQ3™.
Speakers will include:
Butterfly will also be joined by strategic partners introducing AI tools and novel products that are in co-development.
Attendance at the event will be reserved for analysts and institutional investors. To inquire about attendance at the event, please reach out to This email address is being protected from spambots. You need JavaScript enabled to view it. and This email address is being protected from spambots. You need JavaScript enabled to view it..
A copy of the presentation materials and replay of the event will be available following the event on Butterfly’s Events & Presentations page on the investor relations website.
About Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011, Butterfly Network is a digital health company with a mission is to democratize medical imaging by making high-quality ultrasound affordable, easy-to-use, globally accessible, and intelligently connected, including for the 4.7 billion people around the world lacking access to ultrasound. Butterfly created the world's first handheld single-probe, whole-body ultrasound system using semiconductor technology, Butterfly iQ. The company has continued to innovate, leveraging the benefits of Moore’s Law, to launch its second generation Butterfly iQ+ in 2020, and third generation iQ3 in 2024 – each with increased processing power and performance enhancements. The disruptive technology has been recognized by TIME’s Best Inventions, Fast Company’s World Changing Ideas, CNBC Disruptor 50, and MedTech Breakthrough Awards, among other accolades. With its proprietary Ultrasound-on-Chip™ technology, intelligent software, and educational offerings, Butterfly is paving the way to mass adoption of ultrasound for earlier detection and remote management of health conditions around the world. Butterfly devices are commercially available to trained healthcare practitioners in areas including, but not limited to, parts of Africa, Asia, Australia, Europe, the Middle East, North America and South America; to learn more about available countries, visit: https://www.butterflynetwork.com/choose-your-country.
Last Trade: | US$2.55 |
Daily Change: | -0.14 -5.20 |
Daily Volume: | 1,999,332 |
Market Cap: | US$475.930M |
February 28, 2025 January 29, 2025 January 13, 2025 January 08, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load